At Kinnate Biopharma, patients play a key role in clinical trials to find new cancer treatments.

Patient and Caregiver Information

If you are interested in learning more about clinical trials, explore this section. To browse Kinnate-sponsored clinical trials, scroll down.

What are clinical trials?

Clinical trials are research studies to learn about potential new treatments in people. Through clinical trials, doctors and researchers learn if an investigational treatments may work and whether they are safe.

Clinical Trials happen in phases

Clinical trials start at Phase 1.

Purpose:

  • Find a safe dose of the investigational drug
  • Decide how the investigational drug should be given
  • See how the investigational drug affects the body and fights cancer

Once Phase 1 is completed then the clinical trial moves to Phase 2.

Purpose:

  • Determine if the investigational drug has an effect on a certain cancer
  • See how the investigational drug affects the body and fights cancer

After the completion of Phase 2 then the clinical trial moves to Phase 3.

Purpose:

  • Compare the investigational drug (or new use of treatment) with the current standard treatment

Who can enroll in Kinnate clinical trials?

At Kinnate, we’re focused on finding new treatments for people with cancers that have certain genetic mutations (changes in genes that cause cancer to grow), and:

  • There are no approved targeted therapies for the genetic mutation in their cancer – (targeted therapy uses medicines to “target” or attack cancer cells with a certain mutation)
  • Approved targeted therapies may not work to treat their cancer
  • Approved targeted therapies that may stop working to treat their cancer

    Find a Kinnate clinical trial to join

    To learn more about our ongoing clinical programs, please read below and visit the Science & Pipeline section of our website. If you have questions about our programs or eligibility for our clinical trials, please contact us.

    Expanded access to investigational medicines prior to regulatory approval
    At Kinnate, we aim to provide patients access to our investigational therapies in the most clinically appropriate manner.  Kinnate does not currently accept or grant requests for expanded access to any of its investigational drugs outside of clinical trials.

    Current Kinnate clinical trials

    A clinical trial of KIN-2787 (study drug) in adults with BRAF-mutation positive cancers and NRAS-mutation positive melanoma (ClinicalTrials.gov Identifier: NCT04913285)

    The main goals of this trial are to learn about:
    • The safety of the study drug
    • How the body tolerates the study drug
    • Whether a participant’s cancer responds to treatment with the study drug
    What treatment will participants get?

    All participants will receive the study drug, which is a targeted therapy that may work for some patients who are diagnosed with a BRAF mutation-positive cancer or NRAS mutation-positive melanoma. For this clinical trial, adult participants will receive daily medicine taken by mouth of the study drug.

    Who can join?

    You may be able to enroll in the clinical trial if you:

    • Have advanced (late stage) or metastatic (spread to other parts of your body)
    • Have a tumor with BRAF mutation or melanoma with an NRAS mutation
    • Can take medications by mouth
    • Can attend study visits and complete study assessments
    How many people will join?

    About 155 people will be in this trial.

    A clinical trial of KIN-3248 (study drug) in adults with advanced solid tumors who have FGFR2 and/or FGFR3 gene mutations (ClinicalTrials.gov Identifier: NCT05242822)

    The main goals of this trial are to learn about:
    • The safety of the study drug
    • How the body tolerates the study drug
    • Whether a participant’s cancer responds to treatment with the study drug
    What treatment will participants get?

    All participants will receive the study drug, which is a targeted therapy designed to stop cancer cells from growing. Participants will take study drug every day by mouth, or in combination with another approved cancer drug.

    Who can join?

    You may be able to enroll in the clinical trial if you:

    • Have FGFR2 and/or FGFR3 gene mutations in cancerous tumors
    • Have a cancer diagnosis of advanced intrahepatic cholangiocarcinoma (also called ICC or bile duct cancer), advanced urothelial cancer (also called UC or bladder cancer), or other advanced cancerous tumors.
    • Can take medications by mouth
    • Can attend study visits and complete study assessments
    How many people will join?

    About 120 people will be in this trial.

    Travel Support for Participants in Kinnate Clinical Trials

    Kinnate will cover travel expenses related to study visits for the participant and one caregiver at select sites that participate in our travel support program. Examples of expenses:

    Airfare 

    Hotel

    Meals

    Parking fees

    Childcare, eldercare, and pet care

    Additional information on travel support will be provided by the site staff, should you elect to participate.

    “Each and every participant in our clinical trials plays an essential role in support of our mission to advance precision cancer medicines, and we are deeply grateful to the patients and caregivers.”

    For questions about our clinical trials, contact our team. 

    Every cancer has a weak spot. We design therapies that take advantage of them.